Portfolio Investment
Search documents
Buy or Sell Meta Stock?
Forbes· 2025-11-19 14:47
Core Insights - Meta Platforms (META) stock has seen a significant decline of 20.5% in less than a month, dropping from $751.67 on October 29, 2025, to $597.69 currently, raising the question of whether this dip presents a buying opportunity [2] - Historically, stocks that experience steep declines of 30% or more within a 30-day period have shown an average return of 75% over the following 12 months, with a median peak return of 85% [2][9] Historical Performance - Since January 1, 2010, Meta Platforms has experienced four instances where the stock dipped by 30% or more within a 30-day timeframe [5] - The median duration to reach peak return after a dip event is 258 days, with a median maximum drawdown of 14% within one year following the dip [9] Financial Quality Assessment - Meta Platforms meets basic financial quality criteria, which include revenue growth, profitability, cash flow, and balance sheet stability, essential for minimizing the risk associated with stock dips [6] - A portfolio approach is suggested for investment decisions, as it can outperform individual stock selection by mitigating the impact of drops in individual stocks [7][8]
Stride Stock: What The Numbers Say About The Road Ahead
Forbes· 2025-11-03 14:55
Core Insights - Stride Inc. has seen a drastic decline in market value, dropping nearly 50% shortly after reporting quarterly results that exceeded earnings expectations, with an adjusted EPS of $1.52 and revenue of $620.9 million, reflecting a nearly 13% year-over-year growth [2] - The company's full-year revenue forecast of $2.48 billion to $2.55 billion fell short of Wall Street's expectations of approximately $2.67 billion, causing investor concern [2][3] - Operational missteps in technology rollout may have resulted in a loss of 10,000–15,000 student enrollments, impacting the company's scale and retention [2] Revenue Growth and Enrollment - The revised guidance indicates a slowdown in revenue growth from approximately 18% last year to an expected 9–10% this year, raising concerns among growth investors [3] - Despite an 11% increase in overall enrollment and Career Learning segment growth exceeding 30%, skepticism remains regarding Stride's ability to maintain profitability if growth momentum declines [3] Financial Metrics and Valuation - Stride is currently trading at around 12–13 times forward earnings, significantly lower than competitors like Chegg or Coursera, which have valuations exceeding 20 times [4] - This low valuation reflects market doubt but also presents potential investment opportunities if management can stabilize enrollments and achieve long-term growth targets of 10% annual revenue growth and 20% profit growth [4]
Dave Ramsey's Portfolio Outperformed by S&P 500, Three-Fund Portfolio Across All Time Frames Over Past 10 Years, Podcaster Says
Yahoo Finance· 2025-10-04 00:02
Core Insights - Personal finance expert Dave Ramsey advocates for a diversified investment portfolio split equally among four categories: growth and income, growth, aggressive growth, and international [2] - A comparison of Ramsey's investment approach with the Vanguard S&P 500 ETF (VOO) and a three-fund portfolio revealed that Ramsey's portfolio returned approximately 8% over the past 10 years, while VOO returned 12% and the three-fund portfolio returned 9% [2] - Over the past five years, Ramsey's portfolio achieved a return of 10%, compared to VOO's 15% and the three-fund portfolio's 12% [2] - The S&P 500 fund outperformed Ramsey's portfolio by 7 percentage points over the past year and by 4 percentage points over the past three years [2][3] - Historically, the S&P 500 has consistently outperformed Ramsey's portfolio across all time frames analyzed [3] Fund Selection - The funds selected for the Ramsey portfolio include: - Columbia Large Cap Index Fund Class A (for growth and income) - JPMorgan Mid Cap Growth Fund Class R3 (for growth) - American Funds EUPAC R4 (for international) - Franklin Small Cap Growth Fund Class A (for aggressive growth) [4]
CAT Stock vs. Peers
Forbes· 2025-10-02 12:20
Core Insights - Caterpillar stock (NYSE: CAT) has surged 16% in a month due to strong fundamentals, including robust demand and a substantial order backlog, indicating strong business momentum and future revenue [3] - The stock has reached new all-time highs, supported by positive technical momentum [3] - A comparison with peers is essential to evaluate CAT's performance in terms of size, valuation, growth, and margins [6] Company Overview - Caterpillar supplies construction and mining equipment, engines, industrial turbines, and financial services, including leases and loans, across various sectors [4] Performance Metrics - CAT's operating margin is 18.2%, which is lower than many competitors, such as ALSN at 31.3% [8] - CAT's revenue growth over the previous 12 months is -4.9%, which is negative and falls short of competitors like ALSN, TEX, and ASTE, but surpasses DE [8] - Over the past year, CAT's stock has increased by 24.5% and is currently trading at a PE ratio of 23.9, while competitors like ASTE have provided better returns [8]
Why JNJ Stock Defines Shareholder Supremacy In Healthcare
Forbes· 2025-09-30 13:45
Core Insights - Johnson & Johnson (JNJ) has demonstrated strong financial performance, exceeding Wall Street's revenue and earnings estimates, driven by growth in its pharmaceutical and medical devices sectors [2] - The company has returned a total of $157 billion to investors over the past decade through dividends and share buybacks, showcasing its commitment to shareholder value [2] - JNJ's stock has delivered a 26% year-to-date return in 2025, outperforming the broader healthcare sector [2] Dividend and Shareholder Returns - JNJ announced its 63rd consecutive year of dividend increases, raising the quarterly dividend by 4.8% to $1.30 per share, reflecting its dedication to rewarding shareholders [3] - The company executed $2.13 billion in share buybacks in the first half of 2025, repurchasing over 13.3 million shares, while continuing to invest in R&D and strategic acquisitions [4][5] - JNJ ranks as the 9th largest company in history for total capital returned to shareholders, emphasizing the importance of dividends and share repurchases as indicators of financial stability [7] Financial Performance - In the second quarter of 2025, JNJ reported revenue of $23.74 billion, marking a 5.8% year-over-year increase, with growth in both the Innovative Medicine and MedTech segments [5] - The company's robust cash generation capabilities support consistent dividend growth and opportunistic share repurchases, reinforcing its financial resilience [5]